{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:18:52Z","timestamp":1772770732737,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1053\/j.seminhematol.2010.06.008","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T05:04:19Z","timestamp":1285736659000},"page":"354-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Stem Cell Transplant for Chronic Myeloid Leukemia in the Imatinib Era"],"prefix":"10.1053","volume":"47","author":[{"given":"Jerald","family":"Radich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.06.008_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-104-2-155","article-title":"Marrow transplantation for the treatment of chronic myelogenous leukemia","volume":"104","author":"Thomas","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib3","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib4","first-page":"379","article-title":"Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse","volume":"5","author":"Devergie","year":"1990","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib5","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood.V72.6.1978.1978","article-title":"HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration","volume":"72","author":"Martin","year":"1988","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib6","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood.V84.12.4368.bloodjournal84124368","article-title":"Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for chronic myelogenous leukemia in chronic phase","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","volume":"70","author":"Tutschka","year":"1987","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib9","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","article-title":"Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib10","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib11","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.V82.7.1954.1954","article-title":"Treatment of chronic myeloid leukemia by marrow transplantation","volume":"82","author":"Clift","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib12","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia","volume":"338","author":"Hansen","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib13","first-page":"537","article-title":"Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome","volume":"17","author":"Enright","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib14","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.V82.7.2235.2235","article-title":"Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase","volume":"82","author":"Goldman","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0002-9343(01)00629-5","article-title":"Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors","volume":"110","author":"Davies","year":"2001","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197902153000702","article-title":"Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin","volume":"300","author":"Fefer","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1056\/NEJM198201143060202","article-title":"Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins","volume":"306","author":"Fefer","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM200101183440303","article-title":"Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers","volume":"344","author":"Bensinger","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood-2002-01-0048","article-title":"A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies","volume":"100","author":"Couban","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbmt.2004.09.010","article-title":"Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia","volume":"11","author":"Oehler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib21","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood.V94.11.3668","article-title":"Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure","volume":"94","author":"Hehlmann","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.leu.2402808","article-title":"Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias","volume":"17","author":"Shimoni","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib23","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705087","article-title":"Imatinib therapy prior to myeloablative allogeneic stem cell transplantation","volume":"36","author":"Zaucha","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib25","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib26","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib27","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib29","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/sj.leu.2403730","article-title":"Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML","volume":"19","author":"Kerbauy","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase","volume":"101","author":"Or","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib32","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib33","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1182\/blood.V89.7.2602","article-title":"Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation","volume":"89","author":"Radich","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib34","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V98.6.1701","article-title":"The significance of bcr-abl molecular detection in chronic myeloid leukemia patients \u201clate,\u201d 18 months or more after transplantation","volume":"98","author":"Radich","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib35","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V90.7.2549","article-title":"Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation","volume":"90","author":"Higano","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib36","first-page":"2177","article-title":"Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results","volume":"8","author":"Kantarjian","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib37","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V99.10.3861","article-title":"Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation","volume":"99","author":"Olavarria","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib38","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib39","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib40","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib41","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2010.491","article-title":"Hematopoietic stem cell transplantation: a global perspective","volume":"303","author":"Gratwohl","year":"2010","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib42","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib43","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib44","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib45","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib46","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib47","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib48","doi-asserted-by":"crossref","unstructured":"McWeeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood;115:315-25.","DOI":"10.1182\/blood-2009-03-210732"},{"key":"10.1053\/j.seminhematol.2010.06.008_bib49","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2009-03-212969","article-title":"The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631000082X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631000082X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:00Z","timestamp":1758522060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719631000082X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S003719631000082X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stem Cell Transplant for Chronic Myeloid Leukemia in the Imatinib Era","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}